Home › Calculator › EBS Dividend Calculator 2026
EBS Dividend DRIP Calculator 2026
23.95% YieldHealthcareEmergent BioSolutions Inc. · NYSE
Price: $8.35 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When EBS pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your EBS snowball 📈
$10,000 in EBS → $3387310.88M in 10 years · $281,129,698,909.19/month
About Emergent BioSolutions Inc. (EBS) — Dividend Analysis 2026
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Compare EBS with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full EBS DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open EBS position with:
🌍 EBS Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold EBS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 23.95% | 21.15% | $2,395 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 20.36% | 17.56% | $2,036 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 19.16% | 16.36% | $1,916 / yr |
| 🇬🇧 UK ISA | 0% | 23.95% | 21.15% | $2,395 / yr |
| 🇬🇧 UK Taxable | 8.75% | 21.85% | 19.05% | $2,185 / yr |
| 🇨🇦 TFSA | 0% | 23.95% | 21.15% | $2,395 / yr |
| 🇨🇦 CA Taxable | 25% | 17.96% | 15.16% | $1,796 / yr |
| 🇦🇺 Super (pension) | 15% | 20.36% | 17.56% | $2,036 / yr |
| 🇦🇺 AU Taxable | 30% | 16.76% | 13.96% | $1,676 / yr |
| 🇩🇪 DE Taxable | 26.375% | 17.63% | 14.83% | $1,763 / yr |
| 🇫🇷 FR Taxable | 30% | 16.76% | 13.96% | $1,676 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 EBS Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 EBS Dividend Payment Schedule
EBS pays quarterly — 4 times per year. Next ex-div: TBD.
📊 EBS vs Healthcare Benchmarks
How EBS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for EBS sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ EBS Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-07-01 | 3,000 | $8.40 | $25.2K | ||
| F-InKind | 2026-06-08 | 694 | $8.00 | $5.6K | ||
| F-InKind | 2026-06-08 | 3,964 | $8.00 | $31.7K | ||
| F-InKind | 2026-06-08 | 2,018 | $8.00 | $16.1K | ||
| F-InKind | 2026-06-08 | 1,741 | $8.00 | $13.9K | ||
| A-Award | 2026-04-30 | 25,344 | — | — | ||
| Sale | 2026-05-01 | 12,781 | $8.36 | $106.8K | ||
| Sale | 2026-05-01 | 980 | $8.94 | $8.8K | ||
| A-Award | 2026-04-30 | 11,296 | $7.99 | $90.3K | ||
| A-Award | 2026-04-30 | 25,344 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where EBS earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the EBS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Emergent BioSolutions Inc. (EBS) is currently trading at $8.35, 93% below its 52-week high. The current dividend yield is 23.95% based on an annual payout of $2.00 per share.
EBS (Emergent BioSolutions Inc.) — 23.95% Dividend Yield Analysis
Emergent BioSolutions Inc. (EBS) is a healthcare stock currently trading at $8.35 with a dividend yield of 23.95%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (23.95%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.